Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Renal Cell
  • Indoles
  • Kidney Neoplasms
  • Pyrroles
  • Quality of Life

abstract

  • This novel tool indicates that baseline FKSI-15 scores were linked to mPFS and mOS in a clear and interpretable way. The results support evaluation of patient-reported QoL symptoms at baseline as a prognostic indicator of survival in clinical research and practice.

publication date

  • February 14, 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3322947

Digital Object Identifier (DOI)

  • 10.1038/bjc.2011.589

PubMed ID

  • 22240794

Additional Document Info

start page

  • 646

end page

  • 50

volume

  • 106

number

  • 4